不宁腿综合征
医学
普瑞巴林
加巴喷丁
病理生理学
羟考酮
疾病
多巴胺能
儿科
糖尿病
重症监护医学
精神科
内科学
类阿片
神经学
病理
内分泌学
多巴胺
替代医学
受体
作者
Claudia Trenkwalder,Richard P. Allen,Birgit Högl,Stefan Clemens,Stephanie M. Patton,Barbara Schormair,Juliane Winkelmann
标识
DOI:10.1016/s1474-4422(18)30311-9
摘要
Restless legs syndrome, also known as Willis-Ekbom disease, is a common neurological condition whose manifestation is affected by complex environmental and genetic interactions. Restless legs syndrome can occur on its own, mostly at a young age, or with comorbidities such as cardiovascular disease, diabetes, and arterial hypertension, making it a difficult condition to properly diagnose. However, the concept of restless legs syndrome as being two entities, primary or secondary to another condition, has been challenged with genetic data providing further insight into the pathophysiology of the condition. Although dopaminergic treatment was formerly the first-line therapy, prolonged use can result in a serious worsening of symptoms known as augmentation. Clinical studies on pregabalin, gabapentin enacarbil, oxycodone–naloxone, and iron preparations have provided new treatment options, but most patients still report inadequate long-term management of symptoms. Studies of the hypoxic pathway activation and iron deficiency have provided valuable information about the pathophysiology of restless legs syndrome that should now be translated into new, more effective treatments for restless legs syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI